A and Neurodegenerative Disorders

While preclinical data from CsA in neurodegenerative disorders was promising, larger studies in Parkinson s disease did not show any benefit along with side complications. Major neurological complications secondary to cyclosporine are well documented and are known to include confusion, cortical blindness, seizure, spasticity, paresis, ataxia and coma. Most previous reports attribute these to white matter CNS lesions or white/grey matter border lesions. Moreover, several publications appeared recently refuted neuroprotective properties of CsA and similar compounds (immu-nophilin ligands). 

So far, none of the inunnne suppressive drugs showed a significant and stable nenroprotective effects in any of the nenro-degenerative conditions. Moreover, under those conditions when steroids were protective they were suggested to mediate the effect directly rather than via snppressing the immune system. 

---